Aptevo Therapeutics近日向美国证券交易委员会（SEC）提交了一份专利申请文件，此次申报的核心内容涉及一项名为“Nectin-4与PD-L1双靶向骨架”的创新技术。该专利旨在开发一种能够同时靶向Nectin-4和PD-L1两个关键免疫检查点的双特异性分子。此举标志着公司在肿瘤免疫治疗领域迈出了重要一步，尤其针对那些在实体瘤中高表达Nectin-4、且依赖PD-L1通路逃避免疫监视的癌细胞。通过这一双靶向骨架，Aptevo希望构建更精准、更高效的抗肿瘤药物平台，从而提升治疗效果并降低潜在副作用。目前，该专利申请已进入官方受理流程，但具体临床前或临床阶段数据尚未随文件一同披露。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.